Compare Ascendis Pharma A/S (ASND) vs Salesforce Inc (CRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Salesforce Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Salesforce Inc trades at $164.58 (market cap $133.76B). The key difference: Salesforce Inc is far larger — about 7.5× Ascendis Pharma A/S's market cap, and Salesforce Inc pays a 1.08% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CRM | |
|---|---|---|
Market Cap | $17.74B | $133.76B |
Sector | Health | Technology |
52-Week High | $277.18 | $270.25 |
52-Week Low | $163.32 | $150.12 |
Enterprise Value | $18.11B | $163.81B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Salesforce (CRM) trades at $163.32, up 0.5% with a bearish technical signal despite strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $3.88 versus $3.13 expected, maintaining robust profitability with 77.64% gross margins and 18.73% net income margin. Recent news highlights AI-driven growth potential but also sector-wide software stock pressures.
Outlook remains positive with analyst consensus target of $235.20 (44% upside), though technical weakness and competitive AI threats pose near-term risks. Revenue growth trajectory and expanding cash flow support long-term value, but investors should monitor sector volatility and execution on AI monetization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
